IPO Listed — 17 Dec 2025

Listing Price: ₹490 (+6.52% vs ₹460)

View GMP History →

IPO Details GMP Review

More sections

Other pages for this IPO

Subscription Allotment

Nephrocare Health Services IPO Review

Q: What does the score of 100 mean for Nephrocare Health Services IPO?

The score of 100 is an aggregate of all analyst ratings tracked for Nephrocare Health Services IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe.

Q: What was the actual listing price of Nephrocare Health Services IPO?

Nephrocare Health Services IPO listed on December 17, 2025 at ₹490, against the issue price of ₹460 — a gain of +6.52% (₹30 per share).

Q: What is the price band and lot size of Nephrocare Health Services IPO?

Nephrocare Health Services IPO is priced at ₹438 – 460 per share. The minimum lot size is 32 shares, making the minimum investment approximately ₹14,016 at the upper end of the price band. Subscription ran from 10 Dec 2025 to 12 Dec 2025.

Nephrocare Health Services IPO has been reviewed by 11 analysts, and the overall consensus is Strong Apply — carrying a score of 100. Out of the 11 analysts who have covered this IPO, 11 recommend subscribing — reflecting a mixed view from the analyst community.

The issue is priced in the band of ₹438 – 460 per share , with a minimum application size of 32 shares (minimum investment of approximately ₹14,016 at the upper band) . Subscription ran from 10 Dec 2025 to 12 Dec 2025. Scroll down for the full analyst breakdown and analyst-wise verdicts.

General Review

Nephrocare Health Services Ltd operates India’s largest organized dialysis network with 519+ clinics domestically and abroad.

Its ₹871.05 crore IPO (Dec 10–12, 2025) priced at ₹438–460 per share saw strong institutional subscription.

Proceeds will fund new clinics, debt repayment, and corporate purposes.

Shares listed with a positive debut on NSE/BSE.

Listing Gains

The notes value the issue between about 57.4 and 67 times FY25 earnings, with EV to EBITDA near 19 to 26 times and an implied market cap around ₹4,615 crore. Analysts describe this as broadly in line with healthcare industry standards, and eleven of thirteen said subscribe.

Short Term Strategy

EBITDA was ₹110.31 crore in the latest period against ₹166.64 crore for the prior full year, on revenue of ₹483.97 crore. One note points out the multiple rises sharply to about 128 times on forecast FY26 earnings, which signals expected near-term margin pressure as the network expands.

Long Term Strategy

Analysts recommend a medium to long-term view, resting on steady growth in dialysis and nephrology care, a service with recurring demand from a chronic patient base. That recurring nature is the core long-term argument, since patients require regular treatment over many years rather than one-off procedures.

Disclaimer: This review is an AI summary derived from the reviews of all analysts.

Analyst Verdict & Score
Detailed Review
Analyst Reviews
Frequently Asked Questions

Analyst Sentiment

Analytical Score

How it's calculated?

Strong Apply

100 / 100

Recommend Subscribe

Based on 11 analyst reviews

11 / 11

Higher consensus indicates broader analyst agreement.

Analyst Review

Analyst	Verdict	View
Adroit Financial Services	Apply
Anand Rathi	Apply
BP Equities	Apply
SBI Securities	Apply
SMIFS Limited	Apply
Lakshmishree Investment	Apply
Capital Market	Apply
Swastika Investmart	Apply
Kunvarji Wealth	Apply
Stoxbox	Apply
Axis Capital	Not rated
Dilip Davda	Not rated	-
Incred equities	Apply

Latest IPO Reviews

Manika Plastech Strong Apply

Score

Veegaland Developers Apply

Score

Rentomojo Apply

Score

Asset Reconstruction Co.(India) Strong Apply

Score

Frequently Asked Questions

Should I apply for Nephrocare Health Services IPO?

Based on analyst coverage tracked on this page, the overall verdict for Nephrocare Health Services IPO is Strong Apply. Out of 11 analysts who have reviewed this IPO, 11 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.

What does the score of 100 mean for Nephrocare Health Services IPO?

The score of 100 is an aggregate of all analyst ratings tracked for Nephrocare Health Services IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Scroll down to read individual analyst verdicts for more context.

What was the actual listing price of Nephrocare Health Services IPO?

Nephrocare Health Services IPO listed on December 17, 2025 at ₹490 , against the issue price of ₹460 — a gain of +6.52% (₹30 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Nephrocare Health Services IPO?

Nephrocare Health Services IPO was priced at ₹438 – 460 per share. The minimum lot size is 32 shares, making the minimum investment approximately ₹14,016 at the upper end of the price band. Subscription ran from 10 Dec 2025 to 12 Dec 2025.

Explore Nephrocare Health Services IPO Further

Track every stage of this IPO:

📈

GMP Today

Live grey market premium

📊

Subscription Status

Real-time bidding data

📋

Allotment Status

Check if you got shares

Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.